Skip to main content
. 2022 Aug 3;9(6):3737–3750. doi: 10.1002/ehf2.14097

Figure 4.

Figure 4

(A) Dispensings of sacubitril/valsartan (S/V) (Entresto®) to statutory health‐insured patients in defined daily doses in Germany from 2016 to 2021 (Source: DAPI database). (B) Number of first‐time S/V patients by month and gender in the IQVIA LRx panel, from January 2016 to December 2021. Absolute numbers as provided in the y‐axis refer to the IQVIA LRx panel that reflects ~80% of the German SHI market. To derive the total number of first‐time S/V patients per month, a correction factor has to be applied (multiply with ~1.5).